CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today provided an update on its fourth quarter 2011 and recent business activities.
“During 2011, we were focused on preparing linaclotide for successful regulatory submissions in the U.S. and Europe, and we continue to put all of the elements in place for a successful product launch while these submissions are under review, including our recent capital raise of $85 million to strengthen our balance sheet,” said Michael Higgins, Ironwood’s chief operating officer and chief financial officer. “We believe that linaclotide’s product profile is highly appealing for both therapy-seeking patients and physicians and we are committed to a successful product launch, if approved.”
